Zepbound vs Wegovy is the decision most people entering medical weight loss now face, and the honest answer is that the right choice is rarely the drug with the biggest headline number. Zepbound (tirzepatide) and Wegovy (semaglutide) are both injectable, once-weekly medications that produce meaningful weight loss, but they work through different mechanisms and suit different patients. Choosing between them is a clinical decision, not a marketing one.

Key Takeaways
  • Zepbound is tirzepatide, a dual GIP/GLP-1 agonist; Wegovy is semaglutide, a single GLP-1 agonist.
  • In trials, tirzepatide produced greater average weight loss, but the right drug depends on the individual.
  • Tolerance, insurance and access, cost, and early response all move the decision.
  • A clinician reads your metabolic labs first, then titrates slowly on either agent.

The mechanism difference

Wegovy's semaglutide is a GLP-1 receptor agonist: it mimics one gut hormone that curbs appetite and slows gastric emptying. Zepbound's tirzepatide is a dual agonist, activating both GLP-1 and GIP receptors, which appears to compound the metabolic effect. That extra receptor is why tirzepatide tends to post larger average losses in trials — but "on average" is doing heavy lifting in that sentence, because individuals are not averages. Our medical weight loss program starts from your physiology, not the leaderboard.

What the trials show

The trial data are strong for both. In the STEP 1 trial, semaglutide produced roughly 15% average body-weight reduction over 68 weeks (STEP 1). In SURMOUNT-1, tirzepatide reached roughly 20% or more at the highest dose (SURMOUNT-1). The gap is real, but so is the variance within each study — plenty of semaglutide patients outperformed the tirzepatide average, and dose, adherence, and baseline metabolism all shift where an individual lands.

See our membership options and how it works to start with a clinician who reads your labs.

Frequently Asked Questions

Is Zepbound more effective than Wegovy?

On average, tirzepatide (Zepbound) produced greater weight loss in trials than semaglutide (Wegovy). But averages hide wide individual variation, and the more effective drug for you is the one your body tolerates and you can stay on.

What is the actual difference between the two?

Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist; Wegovy (semaglutide) is a single GLP-1 receptor agonist. The extra receptor is why tirzepatide tends to post larger average losses in trials.

How does a clinician choose between them?

By reading your metabolic labs, your tolerance history, your insurance and cost picture, and your response in the first eight weeks — then titrating slowly on the better-fit agent.

References

  1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/